The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 12, 2025
Filed:
Feb. 14, 2023
Applicant:
Araxes Pharma Llc, San Diego, CA (US);
Inventors:
Pingda Ren, San Diego, CA (US);
Yi Liu, San Diego, CA (US);
Liansheng Li, San Diego, CA (US);
Jun Feng, San Diego, CA (US);
Tao Wu, Carlsbad, CA (US);
Assignee:
Araxes Pharma LLC, San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 205/04 (2006.01); C07D 211/56 (2006.01); C07D 211/58 (2006.01); C07D 211/60 (2006.01); C07D 211/62 (2006.01); C07D 213/64 (2006.01); C07D 213/74 (2006.01); C07D 231/40 (2006.01); C07D 237/04 (2006.01); C07D 285/14 (2006.01); C07D 285/16 (2006.01); C07D 295/16 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 403/04 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 405/06 (2006.01); C07D 419/12 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/10 (2006.01); G01N 33/58 (2006.01);
U.S. Cl.
CPC ...
C07D 205/04 (2013.01); C07D 211/56 (2013.01); C07D 211/58 (2013.01); C07D 211/60 (2013.01); C07D 211/62 (2013.01); C07D 213/64 (2013.01); C07D 213/74 (2013.01); C07D 231/40 (2013.01); C07D 237/04 (2013.01); C07D 285/14 (2013.01); C07D 285/16 (2013.01); C07D 295/16 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/06 (2013.01); C07D 419/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); G01N 33/58 (2013.01);
Abstract
Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.